Novel strategy for the use of leptin for obesity therapy

Introduction: Obesity is a chronic disease and a major global health challenge. Apart from bariatric surgery, which is costly and not without risk, there are currently no successful long-term treatment options for obesity. The history of pharmacological agents for obesity has been turbulent with many examples of drugs being removed from the market due to significant side effects. Orlistat and sibutramine (the latest drugs on the market) provide only modest weight loss and are both associated with high attrition rates due to intolerable side effects. Furthermore, sibutramine was recently withdrawn from the market. There is a need for the development of safe and efficacious drug treatments for obesity. Areas covered: This review covers the history of leptin therapy as an orphan drug, leptin-replacement therapy as a treatment for obesity, preclinical studies showing the efficacy of leptin/amylin combination and finally, the very promising early clinical findings using pramlintide/meteleptin combination therapy in overweight to obese individuals. Expert opinion: Combination pharmacological therapy, such as pramlintide/metreleptin, for the treatment of obesity is very promising and is supported by encouraging weight loss results and improvement in metabolic makers in early-phase clinical studies. However, the latest randomized clinical trial on pramlintide/metreleptin was recently stopped due to safety concerns.

[1]  R. Seth,et al.  Combined amylin–leptin treatment lowers blood pressure and adiposity in lean and obese rats , 2011, International Journal of Obesity.

[2]  C. Mantzoros,et al.  Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. , 2011, European journal of endocrinology.

[3]  E. Ravussin,et al.  The fall in leptin concentration is a major determinant of the metabolic adaptation induced by caloric restriction independently of the changes in leptin circadian rhythms. , 2011, The Journal of clinical endocrinology and metabolism.

[4]  C. Mantzoros,et al.  Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance , 2011, Diabetes.

[5]  S. Davis,et al.  Pramlintide and the treatment of diabetes: a review of the data since its introduction , 2011, Expert opinion on pharmacotherapy.

[6]  Mary T. Brinkoetter,et al.  Leptin is an effective treatment for hypothalamic amenorrhea , 2011, Proceedings of the National Academy of Sciences.

[7]  R. Leibel,et al.  Effects of chronic weight perturbation on energy homeostasis and brain structure in mice. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[8]  D. Parkes,et al.  Insights into amylin–leptin synergy , 2010, Trends in Endocrinology & Metabolism.

[9]  J. Chan,et al.  Clinical classification and treatment of congenital and acquired lipodystrophy. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[10]  G. Bray,et al.  Combination Drugs for Treating Obesity , 2010, Current diabetes reports.

[11]  F. Greenway,et al.  Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients. , 2010, The Journal of clinical endocrinology and metabolism.

[12]  C. Weyer,et al.  Interaction of Leptin and Amylin in the Long‐term Maintenance of Weight Loss in Diet‐induced Obese Rats , 2010, Obesity.

[13]  D. Parkes,et al.  Mechanisms of amylin/leptin synergy in rodent models. , 2010, Endocrinology.

[14]  X. Pi-Sunyer.  The Medical Risks of Obesity , 2002, Obesity surgery.

[15]  E. Ravussin,et al.  Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy , 2009, Obesity.

[16]  M. Riddle,et al.  Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes , 2009, Diabetes Care.

[17]  C. Weyer,et al.  Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. , 2008, Endocrinology.

[18]  Christian Weyer,et al.  Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.

[19]  J. Chan,et al.  Pharmacokinetics of Subcutaneous Recombinant Methionyl Human Leptin Administration in Healthy Subjects in the Fed and Fasting States , 2008, Clinical pharmacokinetics.

[20]  G. Bray,et al.  Pharmacological Treatment of the Overweight Patient , 2007, Pharmacological Reviews.

[21]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. , 2007, Metabolism: clinical and experimental.

[22]  J. Leahy.  A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes , 2007 .

[23]  T. Lutz.  Amylinergic control of food intake , 2006, Physiology and Behavior.

[24]  S. Heymsfield,et al.  Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. , 2005, The Journal of clinical investigation.

[25]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. , 2005, Diabetes.

[26]  D. Kleiner,et al.  Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy , 2005, Hepatology.

[27]  A. Volpe,et al.  Recombinant human leptin in women with hypothalamic amenorrhea. , 2004, The New England journal of medicine.

[28]  O G Kolterman,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[29]  H. Münzberg,et al.  Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. , 2004, Endocrinology.

[30]  J. Yanovski,et al.  Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  A Tremblay,et al.  Thermogenesis and weight loss in obese individuals: a primary association with organochlorine pollution , 2004, International Journal of Obesity.

[32]  P. Gorden,et al.  Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. , 2004, Metabolism: clinical and experimental.

[33]  L. Orci,et al.  Rapid transformation of white adipocytes into fat-oxidizing machines , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Schwartz,et al.  Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM , 1996, Diabetologia.

[35]  W. Banks,et al.  Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[36]  R. Unger.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0870 Minireview: Weapons of Lean Body Mass Destruction: The Role of Ectopic Lipids in the Metabolic Syndrome , 2022 .

[37]  C. Bouchard,et al.  Greater than predicted decrease in energy expenditure during exercise after body weight loss in obese men. , 2003, Clinical science.

[38]  C. Weyer,et al.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.

[39]  Y. Minokoshi,et al.  Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. , 2001, Biochemical Society transactions.

[40]  Graham M Lord,et al.  Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. , 2002, The Journal of clinical investigation.

[41]  R. Leibel.  The role of leptin in the control of body weight. , 2002, Nutrition reviews.

[42]  D. Mangelsdorf,et al.  PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Petersen,et al.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.

[44]  S. Heymsfield,et al.  Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. , 2002, The Journal of clinical endocrinology and metabolism.

[45]  C. Weyer,et al.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.

[46]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[47]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[48]  C. Weyer,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. , 2001, Current pharmaceutical design.

[49]  R. Unger.  Leptin physiology: a second look , 2000, Regulatory Peptides.

[50]  A. Tremblay,et al.  Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin? , 2000, The Journal of clinical endocrinology and metabolism.

[51]  J. Sturis,et al.  High-frequency oscillations in circulating amylin concentrations in healthy humans. , 2000, American journal of physiology. Endocrinology and metabolism.

[52]  K. Fujioka,et al.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. , 1999, JAMA.

[53]  A. Prentice,et al.  Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.

[54]  M. Roden,et al.  Acute effect of leptin on hepatic glycogenolysis and gluconeogenesis in perfused rat liver , 1999, Hepatology.

[55]  C. Mantzoros,et al.  Leptin in relation to resumption of menses in women with anorexia nervosa , 1998, Molecular Psychiatry.

[56]  A. Klibanski,et al.  Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake. , 1998, The Journal of clinical endocrinology and metabolism.

[57]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[58]  G. Pacini,et al.  Amylin: History and Overview , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[59]  C. Newgard,et al.  Direct antidiabetic effect of leptin through triglyceride depletion of tissues. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Mantzoros,et al.  Role of leptin in the neuroendocrine response to fasting , 1996, Nature.

[61]  W. Colburn,et al.  Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent Diabetes , 1996, Journal of clinical pharmacology.

[62]  B. Lowell,et al.  Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action , 1995, Nature Medicine.

[63]  B. Lowell,et al.  Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. , 1995, The Journal of clinical investigation.

[64]  R. Leibel,et al.  Changes in energy expenditure resulting from altered body weight. , 1995, The New England journal of medicine.

[65]  M. Weintraub,et al.  Long‐term weight control study: Conclusions , 1992, Clinical pharmacology and therapeutics.

[66]  C J Hull,et al.  Pharmacokinetics and pharmacodynamics. , 1979, British journal of anaesthesia.